-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Centessa Pharmaceuticals, Maintains $28 Price Target

Benzinga·03/26/2025 13:47:47
Listen to the news
Guggenheim analyst Debjit Chattopadhyay reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $28 price target.